4.7 Review

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response

Journal

Publisher

MDPI
DOI: 10.3390/ijms22083837

Keywords

melanoma; immunotherapy; genomics; transcriptomics; proteomic; metabolomics; radiomics; liquid biopsy; precision medicine; biomarkers

Funding

  1. Italian Ministry of Health [RC 2021]
  2. Italian Association for Cancer Research (AIRC) fellowship for Italy

Ask authors/readers for more resources

Treatment and management of metastatic melanoma have evolved significantly in the era of personalized medicine, benefiting from immunotherapy and advancements in multi-omics analyses. While improving clinical management, precision medicine plays a crucial role in guiding treatment decisions for individual patients.
The treatment and management of patients with metastatic melanoma have evolved considerably in the era of personalized medicine. Melanoma was one of the first solid tumors to benefit from immunotherapy; life expectancy for patients in advanced stage of disease has improved. However, many progresses have yet to be made considering the (still) high number of patients who do not respond to therapies or who suffer adverse events. In this scenario, precision medicine appears fundamental to direct the most appropriate treatment to the single patient and to guide towards treatment decisions. The recent multi-omics analyses (genomics, transcriptomics, proteomics, metabolomics, radiomics, etc.) and the technological evolution of data interpretation have allowed to identify and understand several processes underlying the biology of cancer; therefore, improving the tumor clinical management. Specifically, these approaches have identified new pharmacological targets and potential biomarkers used to predict the response or adverse events to treatments. In this review, we will analyze and describe the most important omics approaches, by evaluating the methodological aspects and progress in melanoma precision medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Rossella Loria, Valentina Laquintana, Stefano Scalera, Rocco Fraioli, Valentina Caprara, Italia Falcone, Chiara Bazzichetto, Marta Di Martile, Laura Rosano, Donatella Del Bufalo, Gianluca Bossi, Isabella Sperduti, Irene Terrenato, Paolo Visca, Silvia Soddu, Michele Milella, Gennaro Ciliberto, Rita Falcioni, Virginia Ferraresi, Giulia Bon

Summary: This study reveals that high expression of SEMA6A is associated with poor prognosis in BRAF-mutant melanoma and plays a critical role in promoting tumor aggressiveness and resistance to targeted therapies. SEMA6A may serve as a potential predictor for the efficacy of dual BRAF/MEK inhibition.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Oncology

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition

Fabiana Conciatori, Erica Salvati, Ludovica Ciuffreda, Senji Shirasawa, Italia Falcone, Francesco Cognetti, Gianluigi Ferretti, Massimo Zeuli, Donatella Del Bufalo, Chiara Bazzichetto, Michele Milella

Summary: Soluble factors produced by stromal fibroblasts can influence the sensitivity of tumor cells to molecularly targeted drugs. This influence depends on the genetic mutations and PTEN protein status of the tumor cells.

FRONTIERS IN ONCOLOGY (2022)

Article Chemistry, Multidisciplinary

Optimization of Tc-99m-MAA SPECT/CT Imaging for Y-90 Radioembolization Using a 3D-Printed Phantom

Sara Ungania, Marco D'Arienzo, Sandro Nocentini, Marco D'Andrea, Vicente Bruzzaniti, Raffaella Marconi, Emilio Mezzenga, Bartolomeo Cassano, Erminia Infusino, Antonino Guerrisi, Antonella Soriani, Lidia Strigari

Summary: This study aimed to develop a SPECT/CT imaging protocol for quantitative imaging optimization in radioembolization (RE) treatment, using cutting edge imaging technology and a novel anthropomorphic 3D-printed phantom. The results showed that the xSPECT software allowed for absolute quantification in anthropomorphic geometry, but caution is needed when dealing with spherical objects with a necrotic core.

APPLIED SCIENCES-BASEL (2022)

Article Oncology

Microenvironmental Factors in Oral Cavity Squamous Cell Carcinoma Undergoing Surgery: Correlation with Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced MRI

Antonello Vidiri, Andrea Ascione, Francesca Piludu, Eleonora Polito, Enzo Gallo, Renato Covello, Paola Nistico, Vittoria Balzano, Barbara Pichi, Raul Pellini, Simona Marzi

Summary: In this study, the correlation between imaging parameters obtained from magnetic resonance imaging (MRI) and pathological factors in oral cavity squamous cell carcinomas (OSCCs) was investigated. The results showed that pathological factors such as inflammatory infiltrate, tumor grading, and desmoplastic reaction affected the MRI parameters. Significant relationships were found between DKI parameters and tumor-infiltrating lymphocytes (TILs). Differences in DCE-MRI parameters were also observed according to tumor grading. These findings contribute to a better understanding of OSCCs and can be used for diagnostic and prognostic purposes.

CANCERS (2023)

Review Cell Biology

Artificial Intelligence and Advanced Melanoma: Treatment Management Implications

Antonino Guerrisi, Italia Falcone, Fabio Valenti, Marco Rao, Enzo Gallo, Sara Ungania, Maria Teresa Maccallini, Maurizio Fanciulli, Pasquale Frascione, Aldo Morrone, Mauro Caterino

Summary: Artificial intelligence is increasingly being used in the field of medicine, particularly in the treatment of cancer. By processing large amounts of data, AI can assist clinicians in making more accurate treatment decisions, improving patient outcomes.

CELLS (2022)

Review Biochemistry & Molecular Biology

Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach

Elena Ricciardi, Elena Giordani, Giovanna Ziccheddu, Italia Falcone, Patrizio Giacomini, Maurizio Fanciulli, Michelangelo Russillo, Marianna Cerro, Gennaro Ciliberto, Aldo Morrone, Antonino Guerrisi, Fabio Valenti

Summary: Precision medicine has brought about a major change in the treatment of cancer, focusing on the individual and unique characteristics of each patient and tumor. Liquid biopsy, through the analysis of molecules and biomarkers in the blood, presents new opportunities in personalized medicine. Its easy application and lack of contraindications make it applicable in various fields. This review explores the applications and potential developments of liquid biopsy in metastatic melanoma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Computer Science, Interdisciplinary Applications

Development of a somatic variant registry in a National Cancer Center: towards Molecular Real World Data preparedness

Martina Betti, Chiara Maria Salzano, Alice Massacci, Mattia D'Antonio, Isabella Grassucci, Benedetta Marcozzi, Marco Canfora, Elisa Melucci, Simonetta Buglioni, Beatrice Casini, Enzo Gallo, Edoardo Pescarmona, Gennaro Ciliberto, Matteo Pallocca

Summary: The biomedical research field is advancing towards developing clinical trials and translational projects based on real-world evidence. To make this transition feasible, clinical centers need to work towards data accessibility and interoperability. This task is particularly challenging when applied to genomics, which has become routine through amplicon-based next-generation sequencing panels. These experiments produce numerous features per patient, and their results are often stored in static clinical reports, making critical information inaccessible to automated access and federated search consortia. This study presents a reanalysis of 4620 solid tumor sequencing samples in different histology settings and describes the bioinformatics and data engineering processes employed to create a somatic variant registry capable of dealing with the large biotechnological variability of routine genomics profiling.

JOURNAL OF BIOMEDICAL INFORMATICS (2023)

Article Chemistry, Multidisciplinary

New-Generation ASiR-V for Dose Reduction While Maintaining Image Quality in CT: A Phantom Study

Sara Ungania, Francesco Maria Solivetti, Marco D'Arienzo, Francesco Quagliani, Isabella Sperduti, Aldo Morrone, Carlo de Mutiis, Vicente Bruzzaniti, Antonino Guerrisi

Summary: This study aimed to assess the image quality of reduced radiation dose CT images reconstructed with the ASiR-V algorithm and investigate the optimization of image quality parameters. The results showed that ASiR-V algorithm can provide high diagnostic quality images while reducing the patient dose. The best agreement was obtained for the images reconstructed using ASiR-V with NI24 and a high blending percentage (70-100%).

APPLIED SCIENCES-BASEL (2023)

Article Medicine, Research & Experimental

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

Patrizio Giacomini, Fabio Valenti, Matteo Allegretti, Matteo Pallocca, Francesca De Nicola, Ludovica Ciuffreda, Maurizio Fanciulli, Stefano Scalera, Simonetta Buglioni, Elisa Melucci, Beatrice Casini, Mariantonia Carosi, Edoardo Pescarmona, Elena Giordani, Francesca Sperati, Nicoletta Jannitti, Martina Betti, Marcello Maugeri-Sacca, Fabiana Letizia Cecere, Veronica Villani, Andrea Pace, Marialuisa Appetecchia, Patrizia Vici, Antonella Savarese, Eriseld Krasniqi, Virginia Ferraresi, Michelangelo Russillo, Alessandra Fabi, Lorenza Landi, Gabriele Minuti, Federico Cappuzzo, Massimo Zeuli, Gennaro Ciliberto

Summary: This study provides insights into the practices of Molecular Tumor Boards (MTB) in the real-world setting, discussing topics such as actionable alteration mapping and outcome metrics. The results show that a significant percentage of patients have actionable alterations, but many of them do not have access to the corresponding treatments. Additionally, combining tDNA and ctDNA testing can improve the detection rate of actionable alterations. It is suggested that better guidance and more efficient drug access channels are needed to improve treatment outcomes for patients with actionable but unexploited alterations.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Article Cell Biology

Bcl-2 family inhibitors sensitize human cancer models to therapy

Elisabetta Valentini, Marta Di Martile, Matteo Brignone, Marica Di Caprio, Isabella Manni, Michela Chiappa, Ilaria Sergio, Martina Chiacchiarini, Chiara Bazzichetto, Fabiana Conciatori, Simona D'Aguanno, Carmen D'Angelo, Rino Ragno, Michelangelo Russillo, Gianni Colotti, Francesco Marchesi, Maria Laura Bellone, Fabrizio Dal Piaz, Maria Pia Felli, Giovanna Damia, Donatella Del Bufalo

Summary: BH3 mimetics, which target the anti-apoptotic proteins of the Bcl-2 family, have shown promising therapeutic potential in cancer treatment. IS21, a novel pan BH3 mimetic, has been found to have preclinical antitumor activity in various types of tumors. IS21 demonstrated activity in T-cell acute lymphoblastic leukemia, melanoma, lung, pancreatic, and ovarian cancer cell lines.

CELL DEATH & DISEASE (2023)

Article Engineering, Electrical & Electronic

Direct Competitive Assay for ERBB2 Detection in Breast Cancer Cell Lysates Using 1-D Photonic Crystals-Based Biochips

Alberto Sinibaldi, Matteo Allegretti, Norbert Danz, Elena Giordani, Peter Munzert, Agostino Occhicone, Patrizio Giacomini, Francesco Michelotti

Summary: ERBB2 is a major cancer driver and a recognized therapeutic target in many cancers, especially breast cancer. Researchers have developed a new approach using a direct competitive ERBB2 assay and 1-D photonic crystal-based biochips. These biochips allow label-free/fluorescence mode operation for ERBB2 biosensing in lysates from breast cancer cells and provide highly specific ERBB2 detection. The assay's main advantage is its single-step detection procedure, reducing assay turnaround time to less than 20 min, making it highly efficient for rapid detection of ERBB2 in complex biological media.

IEEE SENSORS LETTERS (2023)

No Data Available